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INTROdUCTION
Impairments in insight, or unawareness of illness, is a highly prevalent symptom of pati ents with a psychoti c disorder (Amador and Gorman, 1998) . Insight is typically considered a multi -dimensional concept, that includes the following aspects: (i) awareness of illness, (ii) need for treatment, and (iii) relabeling of symptoms (David, 1990) . Impaired insight has adverse consequences on outcomes of the disease, including functi onal outcome, treatment adherence, and re-admissions (Drake et al., 2007) . Multi ple factors have been associated with reduced insight, including neurocogniti ve impairment, social cogniti on, and clinical symptoms (Aleman et al., 2006; Mintz et al., 2003) . However, the majority of the studies investi gati ng insight applied a cross-secti onal design, leaving the questi on whether the above factors contribute to the course of insight over ti me unanswered. This may be parti cularly relevant informati on for clinicians to be able to develop treatment strategies to improve insight.
In schizophrenia, opposed to other psychoti c disorders, impairments in multi ple domains of neurocogniti on (i.e. verbal learning and memory, att enti on/vigilance)have been related to insight (Aleman et al., 2006) . Only a few studies have investi gated the course of insight longitudinally. Parellada et al. (2011) demonstrated that cogniti ve impairments predicted several aspects of insight aft er two years. However, their assessment did not include all of the neurocogniti ve domains defi ned (Nuechterlein et al., 2004) . A second study failed to fi nd a signifi cant eff ect of neurocogniti on on future insight (Cuesta et al., 2006) . In a third study, pati ents with improved insight were found to have bett er cogniti ve performance aft er six months on some tasks, but not all (Cuesta et al., 2011) . However, these fi ndings may have been the result of their inclusion of medicati on-naïve pati ents with a fi rst psychoti c episode at baseline. Therefore, although it has been suggested that cogniti ve impairments limit the response to psycho-social treatment (Lysaker et al., 2002) , this hypothesis has not been addressed adequately with respect to insight improvement.
Previously we demonstrated that social cogniti on and clinical symptoms are both uniquely related to level of insight, irrespecti ve of neurocogniti ve functi oning; interesti ngly, phase of illness moderated this eff ect (Quee et al., 2011) . Taking these fi ndings into account, it is interesti ng to study whether these factors are also predicti ve of changes in insight. In additi on, it is not known whether changes in these factors fl uctuate with changes in insight change. Increases in severity of clinical symptoms have been found to be associated with decreases in insight, but only in pati ents with recent onset psychosis (Buchy et al., 2012) .
In the current study we investi gated factors associated with change in insight over ti me in a longitudinal design. We expected that neurocogniti on and social cogniti on would explain changes in insight over ti me. We also investi gated whether changes in neurocogniti on, social cogniti on, clinical symptoms, and phase of illness were associated with changes in insight.
METhOdS
Participants
Two hundred and seventy patients with psychotic disorders were assessed with the Birchwood Insight Scale at baseline (see paragraph 2.2.1). This was a subsample of the patient population participating in the GROUP project (Korver et al., 2012) . The GROUP project is a large-scale multi-center study that investigates the vulnerability and protective factors for (1) the development of a psychotic disorder, and (2) the variation of the course of illness. Two out of four centers participated in the insight study (Amsterdam and Utrecht). Diagnoses were confirmed using the Comprehensive Assessment of Symptoms and History (CASH) (Andreasen et al., 1992) . The procedure of recruitment, informed consent, assessment instruments, approval by an accredited Medical Ethics Review Committee and population characteristics have been described in a previous report on the project (Korver et al., 2012).
Assessments
Insight
Insight was assessed using two measures. From the Positive And Negative Syndrome Scale (PANSS) (Kay et al., 1987) , a semi-structured interview consisting of 30 items, we used item G12 (Poor Judgment and Insight). Scores on the PANSS range from 1 (absent) to 7 (extremely severe). Secondly, we used the Birchwood Insight Scale (BIS) (16). The BIS is a short self-rating questionnaire that consists of eight questions addressing the three components of insight in psychosis (Awareness of Illness, Need for Treatment, and Relabeling of Symptoms). The BIS total score ranges from 0 to 12, with higher scores indicating better insight. For insight, as well as neurocognition, social cognition, and clinical symptoms, composite measures were created (see paragraph 2.3). For insight, the composite measure consisted of the PANSS item G12, and the BIS.
Neurocognition
The neurocognitive measures used in the GROUP-study have been described in detail elsewhere (Meijer et al., 2011) . The following tasks were administered: Continuous Performance Test -HQ (CPT-HQ) (attention/vigilance), Response Set-shifting Task (RST) (reasoning and problem solving), short form of the Wechsler Adult Intelligence Scale -III (WAIS-III) containing the subtests Block Design (reasoning and problem solving), Digit Symbol (processing speed), Arithmetic (working memory), and Information (verbal comprehension) (Blyler et al., 2000) , Word Learning Task (WLT) immediate recall and delayed recall (verbal learning and memory) (Brand and Jolles, 1985) . Educational degree was assessed using 9 categories, 0 being the lowest (no education) and 8 being the highest (academic degree) (Verhage, 1964) . The parameters used for neurocognition were similar as in our previous study (Quee et al., 2011) , with a few excepti ons. For the CPT-HQ, two parameters were created: CPT variance and CPT performance index. For CPT variance, or intra-individual variability (20), the standard deviati on of the subject's mean response ti me on the hit trials was used. CPT performance index consisted of an effi ciency score ((accuracy/reacti on ti me) x 1000), in which accuracy was measured as the total number of hits (range 0-28) minus the total number of errors (range 0-28), divided by 28. The RST parameter was based on the subjects' accuracy during the experimental conditi on, during which the subject has to fi nd the alternated response rule. For all neurocogniti ve tests, higher scores indicated bett er performances, except for CPT variance.
Social Cogniti on
For social cogniti on, the Degraded Facial Aff ect Recogniti on task (DFAR) (emoti on percepti on) ( Van 't Wout et al., 2004) and the Hinti ng Task (Theory of Mind) (Corcoran et al., 1995) were used. Higher scores on the measures of social cogniti on refl ected bett er performances. The Hinti ng Task was measured at baseline only.
Clinical Symptoms
Current symptom severity was measured with the PANSS. Items on the PANSS incorporate the behavioural eff ect of the symptoms, as well as their severity. As in our earlier study (Quee et al., 2011) we calculated a mean score of the subject's rati ngs on the 8 remission items (Andreasen et al., 2005) . These items include: delusions (P1), conceptual disorganizati on (P2), hallucinatory behaviour (P3), blunted aff ect (N1), social withdrawal (N4), and lack of spontaneity (N6), mannerisms/posturing (G5), and unusual thought content (G9).
Phase of Illness
Phase of illness was divided into recent onset psychosis and multi ple or chronic psychosis. Recent onset psychosis was defi ned as follows: a fi rst psychoti c episode during the year prior to the baseline assessment. All other pati ents were characterized as having 'multi ple episode or chronic psychosis'.
Stati sti cal Analysis
Normality was checked for all variables. If necessary, variables were transformed to approximate normality using logarithmic or square root transformati on. Subsequently, a composite measure was created for the insight measures at baseline and follow-up. As in our previous study, the scores on the G12 and BIS were transformed into z-scores, based on the mean and standard deviati on of the baseline assessment (Quee et al., 2011) . Insight change was computed by subtracti ng the insight composite score at baseline from the insight composite score at follow-up. Thus, higher scores at insight change refl ect more insight improvement. A paired t-test was used to investigate differences between baseline and follow-up insight.
Next, composite scores were creased for baseline neurocognition, cognition, and clinical symptoms. The composite score included all test scores of each of the abovementioned factors (see paragraph 2.2.2, 2.2.3, and 2.2.4). For neurocognition and social cognition, this was done by transforming all the raw scores into z-scores, using the mean and standard deviations from the patient population included at baseline (N=270). For neurocognition, the composite score consisted of 8 measures: CPT-HQ (average performance index and variance, the latter being negatively transformed), RST, WAIS-III Digit Symbol, Block Design, Arithmetic, and Information, WLT (average immediate and delayed recall), and educational degree. For clinical symptoms, a mean score was created, based on the 8 PANSS items.
Hierarchical regression analyses investigated the predictive value of neurocognition, social cognition, clinical symptoms, and phase of illness at baseline. These variables were entered block-wise, which enabled us to investigate the explained variance of neurocognition, as well as the additional explained variance of social cognition, clinical symptoms, and phase of illness. Age at baseline and sex were entered in the first block, as covariates. Scatterplots were used to evaluate the direction of the effects. Changes ≥ 1 SD were considered insight improvement, whereas changes ≤ -1 SD were considered insight decrease.
Next, we analyzed whether changes in neurocognition, social cognition, clinical symptoms and phase of illness were related to insight change. This was done by subtracting the score at baseline from the score at follow-up. These change scores were then transformed into z-scores to create a composite measure for neurocognition. Thus, for neurocognition change as well as social cognition, higher change scores indicated improved performance; for clinical symptoms change, higher scores indicated more symptoms. Variables were entered blockwise in a new regression analysis, again with the covariates age and sex in the first block.
All analyses were performed with 2-tailed hypothesis testing, with α = .05. For the evaluation of the scaled scores, and composite measures, we allowed for 30% of missing values. Statistical analyses were performed using SPSS 18.0. For descriptive purposes, correlations between all variables are displayed in Supplementary Table S1 .
RESUlTS
descriptives
Out of the 270 patients assessed with the assessment of insight at baseline, 154 were assessed in GROUP at follow-up. Dropout in Utrecht and Amsterdam was relatively similar (45% and 55%, respectively). These patients (n=116) received a questionnaire to investigate reasons for dropout; however none of these patients responded to this request. Insight at baseline of the remaining patients differed significantly from the dropout patients (F(1,272)=12.649, INSIGHT CHANGE | p<.001), with the former having higher levels of insight (z=.16, z=-.19, respecti vely) . The eff ect size is this diff erences was small (d=.46), suggesti ng that the sample is sti ll relati vely reliable. Diff erences were also signifi cant for educati on (F(1,272)=7.605,p=.006), but not for neurocogniti on, social cogniti on, clinical symptoms, phase of illness, age, and sex. Table 1 shows the demographic and clinical data for the included 154 pati ents of the current study. At baseline, 21% of the pati ents included had a recent onset psychosis. 
Insight change: relati onship with baseline insight
The diff erence between insight at baseline and follow-up was not stati sti cally signifi cant (p=.388). The relati onship between insight at baseline and insight at follow-up was signifi cant (r=.415,p<.001). Furthermore, baseline insight was signifi cantly related to insight change (r=.515,p<.001), with bett er insight at baseline being associated with more insight improvement.
Insight change: relati onships with baseline neurocogniti on, social cogniti on, clinical symptoms, and phase of illness
Insight change was signifi cantly related to baseline neurocogniti on (r=.231, p=.005), and clinical symptoms (r=-.215, p=.009). Bett er baseline neurocogniti ve performances were related to improvements in insight aft er 3 years (Figure 1 ). Pati ents with more symptoms at baseline had decreased insight (Figure 2) . The relati onship with social cogniti on and phase of illness was non-signifi cant. When neurocogniti on and clinical symptoms were entered in the regression analysis consecuti vely, with age and sex as covariates, the additi onal explained variance of clinical symptoms was signifi cant. Together, these factors explained insight improvement for 10% (Table 2) .
Insight change: relati onships with changes in neurocogniti on, social cogniti on, and clinical symptoms
Insight change was signifi cantly related to change in clinical symptoms (r=-.223, p=.008) . Decreases in clinical symptoms over ti me were related to increases in insight. The relati onships with change in neurocogniti on, social cogniti on, and phase of illness were non-signifi cant. When change in clinical symptoms was entered in the regression analysis, with age and sex as covariates, the explained variance of the model was 12%, with the contributi on of clinical symptoms being signifi cant (β=-.324, p<.001) ( Table 3 ). 
dISCUSSION
The current study investigated factors associated with insight change in non-affective psychosis. Results can be summarized as follows. Most importantly we found that, though the mean group-level of insight was relatively stable over time, improvement of insight within patients was positively related to baseline neurocognitive performances, and negatively related to baseline symptom severity. In addition, changes in insight were found to fluctuate with changes in symptom severity, but not with changes in neurocognition, between baseline and follow-up. The course of insight was stable in the majority of this relatively young population. This is in line with findings that interventions to date had only limited success in improving insight over time (Pijnenborg et al., 2012; unpublished data) . It therefore becomes relevant to study the underlying factors of this insight stability. Longitudinal studies focusing on insight have provided mixed results (Cuesta et al., 2006; Cuesta et al., 2011; Parellada et al., 2011; ) . Rather than predicting the future level of insight, our study focused on factors contributing to changes in insight. The advantage of this approach is that by using a difference score as the outcome measure, both the level of insight at baseline, as well as insight at follow-up are taken into account.
In line with the hypotheses, baseline neurocognition substantially contributed to insight change, together with clinical symptoms. This shows that neurocognition has a rate-limiting effect on the development of insight. Baseline symptom severity and decreases in symptoms over time were associated with an increase in insight as well. This may indicate that treatment of symptoms may be partly beneficial to improve insight in psychosis. In a subsequent analysis, we found that some of the neurocognitive abilities and clinical symptoms may be particularly responsible for this (Supplementary Table S1 ). The relationship between these significant variables should be tested in a new sample to confirm their predictive value on insight change.
In contrast to our expectations, phase of illness and social cognition were not related to insight change. Therefore, insight change may not differ between recent onset patients and other patients. On the other hand, it cannot be ruled out that the correlates of insight change would differ in a study covering a longer period of time. In an earlier study, we found social cognition to be of additional value for insight as well (Quee et al., 2011) . Social cognition has been found to mediate the relationship between neurocognition and functional outcome (Andreasen et al., 2005) . Neurocognitive impairments may thereby underlie the deficits in emotion perception and theory of mind, and this may also apply to the enduring impairments in insight.
The current study may have clinical implications. It has been suggested that patients with more severe neurocognitive impairments are less able to profit from psycho-social interventions (Schmidt et al., 2011) . This may also explain why they only minimally improve
